Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Who We Are
Research Investment
Research
Career Development Program FAQ
News
LLS Applauds Data from Celator Study of CPX-351 for High-Risk AML Patients
White Plains, N.Y. (June 24, 2015) – Interim data released today by Celator Pharmaceuticals regarding its study of CPX-351, a special formulation of …
Who We Are
Surviving AML: The Long Road Back
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
